Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis

Shen, Liang; Sun, Chun; Li, Xue Tao; Liu, Chuan Jin; Zhou, You

doi:10.1007/s10072-015-2269-z

Cited by 37 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were also reflected from the analysis conducted by Liang Shen et al in children with intracranial tumors, craniopharyngioma, medulloblastoma, astrocytoma, or glioma [24]. Ideally, this result should be confirmed by a large-scale multicenter prospective randomized study with sufficiently long follow-up duration.…”

Section: Resultssupporting

confidence: 75%

“…And another meta-analysis showed that the risk of recurrence for pediatric brain tumors was not increased in patients treated with GH [23]. Open Journal of Endocrine and Metabolic Diseases [24]. And a study of pediatric GH treatment which conducted by Child C.J et al also showed that if there has no history of malignancy, the risk of primary cancer did not increase.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

Zeng¹,

Song²,

Lin³

et al. 2017

OJEMD

View full text Add to dashboard Cite

The growth hormone (GH) replacement therapy in adult growth hormone deficiency (AGHD) is now well developed, nevertheless, the safety of GH replacement, especially the incidence of cancer in these patients remains to be further clarified. To summarize the evidence on the safety of using GH in AGHD, we conduct this meta-analysis to assess the relationship between the risk of cancer and GH replacement therapy. Randomized controlled trials and cohort studies involved in GH therapy for AGHD were selected. Meta-analysis was performed and risk ratio (RR) was pooled with 95% confidence interval (CI) to investigate the relationship between GH replacement and the risk of cancer. The result indicated that there was no evidence to draw a conclusion that GH replacement therapy will increase the risk of cancer (P = 0.001, RR = 0.77, 95% CI [0.65, 0.90]). Meanwhile, according to the calculated analysis, the replacement therapy might even reduce the risk of cancer. Furthermore, subgroup analysis demonstrated that there was no correlation between replacement therapy of GH and the risk of cancer both in prospective and retrospective cohort design research, and in prospective group, the risk of cancer even decreased (P = 0.0002, RR = 0.71, 95%CI [0.59, 0.85]). In conclusion, our study corroborates evidence from previous studies showing that GH replacement therapy in AGHD patients would not increase the risk of cancer; instead, it might be even decrease cancer risk. The results suggested that GH replacement therapy in AGHD patients was safe.#These authors contributed equally to this work.

show abstract

Section: Resultssupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

Zeng¹,

Song²,

Lin³

et al. 2017

OJEMD

View full text Add to dashboard Cite

show abstract

“…Despite the undeniable anti-apoptotic and anabolic effect of GH, the exact mechanism by which tumor cells are unprotected remains unknown; thus, the threat of increased future cancer risk or tumor recurrence, impedes its clinical use in oncological patients. However, several data from long-term patient surveillance and meta-analysis studies suggest the safety of low-dose GH treatment, concluding that GH therapy does not increase the risk of cancer (38)(39)(40). Further investigations are highly recommended to establish the clinical applicability of GH in cancer patients treated with chemotherapy and to explore the possible interference with the anti-tumor activity of cytotoxic drugs.…”

Section: Discussionmentioning

confidence: 99%

Growth hormone modulates the inflammatory and apoptotic pathways incorporated in fluorouracil-induced oral mucositis in rats

Serwi

Darwish

Mahran

2020

Egyptian Dental Journal

View full text Add to dashboard Cite

Introduction:Oral mucositis (OM) is a well-known complication of radiotherapy (RT) and chemotherapy (CT) in cancer patients. Although, 5-flourouracil (5-FU) is one of the standard cytotoxic therapies, it is one of the most common causes of OM, which results in delay, dose reduction or treatment discontinuation, thus this intensifies the need for an effective chemoprotective agent. We aimed to investigate the potential chemoprotective effect of growth hormone (GH) on 5-FU-induced OM in rats. Material & Methods:Rats were either exposed to a single 5-FU injection (160 mg/kg ip) and/or treated with GH (1 mg/kg s.c). Oxidative stress, inflammatory and apoptotic markers were assessed.Results: An array of mucosal damage was produced as a result of 5-FU injection, which was evident by histopathology. 5-FU induced a remarkable increase in lipid peroxidation accompanied with a significant depletion of glutathione level. Besides, inflammatory cascades, including NF-κB and IL-6, were elevated significantly. Furthermore, 5-FU stimulated cell death through the significant increase of caspase-3. Interestingly, Pre-treatment with GH markedly ameliorated the deleterious effects of 5-FU through counteracting the oxidative stress and inflammation-mediated apoptosis. In addition, GH rescued the oral mucosal histology following chemotherapy. Conclusions:Our study is the first to demonstrate evidences for the effective chemoprotection provided by GH against 5-FU induced OM along with the underlying mechanisms, which may offer a promising adjuvant therapy for cancer patients.

show abstract

“…In addition, we performed sensitivity analyses to investigate the stability of the overall estimation with respect to each study by excluding studies one by one. Additionally, Begg's and Egger's tests were adopted to assess publication bias (Shen et al., ).…”

Section: Methodsmentioning

confidence: 99%

Acute Alcohol Exposure and Risk of Mortality of Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Ding

Wang

Shen

et al. 2017

Alcohol Clin Exp Res

Self Cite

View full text Add to dashboard Cite

After traumatic brain injury (TBI), patients usually live with significant disability and socioeconomic burdens. Acute exposure to alcohol is considered a major risk factor for TBI. Numerous studies have examined whether alcohol exposure is related to the risk of mortality in patients with TBI, yet the results remain inconsistent. We performed a meta-analysis to assess whether acute alcohol exposure affects the mortality rate of TBI patients. We searched PubMed, EMBASE, and the Cochrane Library up to November 2015 for relevant studies. We screened studies based on their inclusion criteria and selected the studies that reported mortality rate, which included 18 observational studies. We used R to analyze the included data. An initial result showed that the presence of a positive blood alcohol concentration (BAC) had no significant relation with mortality rate (OR = 0.92, 95% CI = 0.83 to 1.01), but there was notable heterogeneity along with variable results according to sensitivity analysis. For the BAC-positive population, low BAC (1 to 100 mg/dl) carried a higher risk of mortality than moderate BAC (100 to 230 mg/dl) (OR = 1.40, 95% CI = 1.09 to 1.81), moderate and high BAC as a single category (>100 mg/dl) (OR = 1.57, 95% CI = 1.28 to 1.94), or high BAC (>230 mg/dl) (OR = 1.76, 95% CI = 1.34 to 2.30). However, moderate BAC did not increase the mortality risk when compared with high BAC (OR = 1.20, 95% CI = 0.89 to 1.63). Whether positive BAC at the time of admission after TBI reduces mortality rate compared with the rate under negative BAC remains unknown. In addition, low BAC (1 to 100 mg/dl) poses a risk of mortality compared with higher BAC. Further studies assessing the effect of alcohol between the BAC-positive group and the BAC-negative group are still needed.

show abstract

Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis

Cited by 37 publications

References 35 publications

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

Growth hormone modulates the inflammatory and apoptotic pathways incorporated in fluorouracil-induced oral mucositis in rats

Acute Alcohol Exposure and Risk of Mortality of Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About